Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $79.6K | $963.1K | $2,663.0K | $7,032.2K | $472.0K | $476.9K | $1,862.7K | $2,826.9K | $4,552.0K | $3,559.2K | $3,711.2K | $0.0 | $3,853.8K | $46.7M | $74.8M | $608.4K | $860.0K | $1,809.0K | ($1,809.7K) | ($2,050.0K) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Summit Therapeutics Inc.'s last 12-month Gross Profit is ($907.0K), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Summit Therapeutics Inc.'s Gross Profit growth was (49.8%). The average annual Gross Profit growth rates for Summit Therapeutics Inc. have been N/A over the past three years, N/A over the past five years.